

Remote Decentralised Clinical Trials

Improving clinical trials' efficacy and effectiveness

Name of Project: Trials@Home

Duration: 2019-2024

Funded by: Innovative Medicines Initiative 2



Background & Objectives

In a **traditional setting**, clinical trial **participants must regularly visit a clinical trial centre** for face-to-face evaluation.

This is not only **burdensome** for the participant, but also **potentially hinders the trials' recruitment process and lowers retention rates**. This leads to clinical trials being inefficient, expensive and sometimes invalid.

Remote Decentralised Clinical Trials (RDCTs) happen in a participant's home setting through digital tools and have the potential to **remedy some of the traditional clinical trials' major constraints**. They potentially also allow for broader participation.

If successful, RDCTs could make it easier to recruit and retain larger numbers of patients, including people from groups that are often under-represented in trials. Continuous data collection can also be more representative of the real world.

Diabetes is the chosen therapeutic area for this project.

IDF Europe's Role

- ✓ Represent the perspectives of people living with diabetes as an association and via people living with diabetes on a Patient Expert Panel, across all aspects of the project.
- ✓ Participate in all communications and dissemination activities.

Deliverables

- A pan-EU pilot to compare traditional clinical trial approaches to full and hybrid RCDT approaches
- Recommendations on set up and feasibility of RDCTs including use of technology, available tools, ethical and regulatory frameworks
- Training kits for deploying pan-EU RCDTs for principal investigators, HCPs, patients, inspectors, pharmaceutical companies and clinical research organisations.
- Virtual education/information sessions for company providers/developers of technologies.

Expected Impact

- Higher speed, quality and efficacy and lower overall costs of clinical trials
- More representative data sets and broader range of real world evidence
- Reduced trial burden, improved recruitment and retention rates
- Faster development of innovative treatment



Scan the QR code for more information and a complete list of the project partners.

The research leading to these results has received support from the EU/EFPIA Innovative Medicines Initiative [2] Joint Undertaking (H2020-JTI-IMI2) Trials@Home grant n° 831458.